Edition:
United States

Profile: Antares Pharma Inc (ATRS.O)

ATRS.O on Consolidated Issue listed on NASDAQ Capital Market

2.82USD
21 Apr 2017
Change (% chg)

$0.06 (+2.17%)
Prev Close
$2.76
Open
$2.83
Day's High
$2.95
Day's Low
$2.76
Volume
3,141,195
Avg. Vol
1,087,173
52-wk High
$3.10
52-wk Low
$0.79

Antares Pharma, Inc. (Antares), incorporated on April 29, 2005, is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.

The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector. OTREXUP, which utilizes VIBEX auto injector, is indicated for adults with severe active rheumatoid arthritis (RA), children with active polyarticular juvenile idiopathic arthritis (pJIA) and adults with severe recalcitrant psoriasis. It has marketing rights for OTREXUP across the world and to commercialize OTREXUP on its own in the United States for the treatment of RA. The Company is conducting clinical studies of Vibex QS T, for testosterone replacement therapy. It also offers Vibex QS M. It has positive top-line pharmacokinetic results that showed that the primary endpoint was achieved in the Company's ongoing, multi-center, phase III clinical study (QST-13-003) evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot auto injector in testosterone deficient adult males. The Company is also developing VIBEX with Sumatriptan for the acute treatment of migraines.

The Company's development projects in collaboration with Teva Pharmaceutical Industries, Ltd. (Teva) include VIBEX epinephrine, an exenatide multi-dose pen, and another undisclosed multi-dose pen. It also makes a reusable, needle-free, spring-action injector device known as ZOMA-Jet or Twin-Jector, which is marketed for use with hGH. The Company has two gel-based products, which are commercialized through various partners of the Company. Its oxybutynin gel product, Gelnique, is used for the treatment of overactive bladder (OAB), and is being marketed in the United States under a licensing agreement with Actavis plc (Actavis). Elestrin (estradiol gel) is marketed by Meda Pharmaceuticals, Inc. (Meda) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.

The Company competes with Teva, Pfizer, Inc., Mylan, Inc., Bedford Laboratories, Hospira, Accord Healthcare, GSK, ENDO Pharmaceuticals, Sun Pharma, Dr. Reddy's Laboratories, Sandoz, Inc., Bedford Labs, Fresenius Kabi, Novo Nordisk, Inc, EMD Serono, Inc., Abbvie, Inc., Lilly, Scandinavian Health Ltd. and Owen Mumford Ltd.

Company Address

Antares Pharma Inc

SUITE 300, 100 PRINCETON SOUTH
EWING   NJ   8628
P: +1609.3593020
F: +1302.6555049

Company Web Links